The introduction of automated insulin delivery (AID) systems represents a significant advancement in diabetes care, offering substantial benefits in outpatient settings. Although clinical studies suggest that these systems can also help improve glycemic control in acutely ill patients, several barriers remain for the actual implementation and use of these technologies in clinical practice. Three main contexts for inpatient use are addressed, including: (a) continuation of personal AID systems, (b) initiation of AID during hospitalization, and (c) initiation of AID systems at discharge. A research road map with immediate to long-term actions is presented. Initially, it calls for clinical studies assessing in-hospital efficacy, safety, and utility, addressing specific patient needs and health care operational impacts. Midterm, it focuses on practical integration, simplifying AID use, ensuring electronic health record compatibility, clarifying regulatory uncertainties, and supporting health care professionals and patients. Long-term goals include system optimizations and policy advocacy for in-hospital AID use.
Get full access to this article
View all access options for this article.
References
1.
ForlenzaGP, LalRA. Current status and emerging options for automated insulin delivery systems. Diabetes Technol Ther, 2022; 24(5):362–371.
2.
KarolAB, O’MalleyG, FallurinR, LevyCJ. Automated insulin delivery systems as a treatment for type 2 diabetes mellitus: A review. Endocr Pract, 2023; 29(3):214–220.
3.
PhillipM, NimriR, BergenstalRM, et al.Consensus recommendations for the use of Automated Insulin Delivery (AID) technologies in clinical practice. Endocr Rev, 2023; 44(2):254–280.
4.
RenardE. Automated insulin delivery systems: From early research to routine care of type 1 diabetes. Acta Diabetol, 2023; 60(2):151–161.
5.
LeeTTM, CollettC, BergfordS, et al.AiDAPT Collaborative Group. Automated insulin delivery in women with pregnancy complicated by type 1 diabetes. N Engl J Med, 2023; 389(17):1566–1578.
6.
PasquelFJ, LansangMC, DhatariyaK, UmpierrezGE. Management of diabetes and hyperglycaemia in the hospital. Lancet Diabetes Endocrinol, 2021; 9(3):174–188.
7.
FortmannAL, Spierling BagsicSR, TalaveraL, et al.Glucose as the fifth vital sign: A randomized controlled trial of continuous glucose monitoring in a non-ICU hospital setting. Diabetes Care, 2020; 43(11):2873–2877.
8.
SinghLG, SatyarenggaM, MarcanoI, et al.Reducing inpatient hypoglycemia in the general wards using real-time continuous glucose monitoring: The glucose telemetry system, a Randomized Clinical Trial. Diabetes Care, 2020; 43(11):2736–2743.
9.
KlarskovCK, WindumNA, OlsenMT, et al.Telemetric continuous glucose monitoring during the covid-19 pandemic in isolated hospitalized patients in Denmark: A Randomized Controlled Exploratory Trial. Diabetes Technol Ther, 2022; 24(2):102–112.
10.
SpanakisEK, UrrutiaA, GalindoRJ, et al.Continuous glucose monitoring–guided insulin administration in hospitalized patients with diabetes: A Randomized Clinical Trial. Diabetes Care, 2022; 45(10):2369–2375.
11.
ThabitH, HartnellS, AllenJM, et al.Closed-loop insulin delivery in inpatients with type 2 diabetes: A Randomised, Parallel-Group Trial. Lancet Diabetes Endocrinol, 2017; 5(2):117–124.
12.
BallyL, ThabitH, HartnellS, et al.Closed-loop insulin delivery for glycemic control in noncritical care. N Engl J Med, 2018; 379(6):547–556.
13.
BoughtonCK, BallyL, MartignoniF, et al.Fully closed-loop insulin delivery in inpatients receiving nutritional support: A Two-Centre, Open-Label, Randomised Controlled Trial. Lancet Diabetes Endocrinol, 2019; 7(5):368–377.
14.
HerzigD, SuhnerS, RoosJ, et al.Perioperative fully closed-loop insulin delivery in patients undergoing elective surgery: An Open-Label, Randomized Controlled Trial. Diabetes Care, 2022; 45(9):2076–2083.
15.
DavisGM, HughesMS, BrownS, et al.Automated insulin delivery with remote real-time continuous glucose monitoring for hospitalized patients with diabetes: A Multi-Center, Single-arm, Feasibility Trial. Diabetes Technol Ther, 2023.
16.
BurnsideMJ, LewisDM, CrocketHR, et al.Open-source automated insulin delivery in type 1 diabetes. N Engl J Med, 2022; 387(10):869–881.
17.
LumJW, BaileyRJ, Barnes-LomenV, et al.A real-world prospective study of the safety and effectiveness of the loop open source automated insulin delivery system. Diabetes Technol Ther, 2021; 23(5):367–375.
18.
GalindoRJ, UmpierrezGE, RushakoffRJ, et al.Continuous glucose monitors and automated insulin dosing systems in the hospital consensus guideline. J Diabetes Sci Technol, 2020; 14(6):1035–1064.
19.
American Diabetes Association Professional Practice Committee. Diabetes care in the hospital: Standards of care in diabetes—2024. Diabetes Care, 2024; 47(Suppl 1):S295–S306.
20.
HughesMS, MorganM, HsuL, et al.976-P: Diabetes technology use in U.S. hospitals. Diabetes, 2024; 73(Supplement_1):976.
21.
UmpierrezGE, KlonoffDC. Diabetes technology update: Use of insulin pumps and continuous glucose monitoring in the hospital. Diabetes Care, 2018; 41(8):1579–1589.
22.
KorytkowskiMT, MuniyappaR, Antinori-LentK, et al.Management of hyperglycemia in hospitalized adult patients in non-critical care settings: An endocrine society clinical practice guideline. J Clin Endocrinol Metab, 2022; 107(8):2101–2128.
23.
SeisaMO, SaadiS, NayfehT, et al.A systematic review supporting the endocrine society clinical practice guideline for the management of hyperglycemia in adults hospitalized for noncritical illness or undergoing elective surgical procedures. J Clin Endocrinol Metab, 2022; 107(8):2139–2147.
24.
RoosJ, SchürchD, FreiA, et al.Time requirements for perioperative glucose management using fully closed-loop versus standard insulin therapy: A proof-of-concept time-motion study. Diabet Med, 2023; 40(9):e15116.
25.
DalyAB, BoughtonCK, NwokoloM, et al.Fully automated closed-loop insulin delivery in adults with type 2 diabetes: An open-label, single-center, randomized crossover trial. Nat Med, 2023; 29(1):203–208.
26.
NamikawaT, MunekageM, YatabeT, et al.Current status and issues of the artificial pancreas: Abridged English translation of a special issue in Japanese. J Artif Organs, 2018; 21(2):132–137.
27.
AndersonTS, LeeAK, JingB, et al.Intensification of diabetes medications at hospital discharge and clinical outcomes in older adults in the veterans administration health system. JAMA Netw Open, 2021; 4(10):e2128998.
28.
BoughtonCK, HartnellS, HobdayN, et al.Implementation of fully closed-loop insulin delivery for inpatients with diabetes: Real-world outcomes. Diabet Med, 2023; 40(6):e15092.
29.
PelkeyMN, BoyleME, LongA, et al.Hybrid closed-loop insulin pump technology can be safely used in the inpatient setting. Endocr Pract, 2023; 29(1):24–28.
30.
Gómez MedinaAM, Henao-CarrilloDC, YepesC, et al.Glycemic control metrics in a cohort of hospitalized patients with type 1 diabetes using hybrid closed-loop and advanced hybrid closed-loop systems. Diabetes Res Clin Pract, 2023; 204:110897.
31.
BallyL, GublerP, ThabitH, et al.Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis. Kidney Int, 2019; 96(3):593–596.
32.
KrutkyteG, RoosJ, SchuerchD, et al.Fully closed-loop insulin delivery in patients undergoing pancreatic surgery. Diabetes Technol Ther, 2023; 25(3):206–211.
33.
KrutkyteG, GoergAMC, GrobCA, et al.Perioperative fully closed-loop versus usual care glucose management in adults undergoing major abdominal surgery—A Two-Centre Randomised Controlled Trial. Ann Surg, 2024; doi: 10.1097/SLA.0000000000006549
34.
OkabayashiT, NishimoriI, MaedaH, et al.Effect of intensive insulin therapy using a closed-loop glycemic control system in hepatic resection patients: A Prospective Randomized Clinical Trial. Diabetes Care, 2009; 32(8):1425–1427.
35.
OkabayashiT, NishimoriI, YamashitaK, et al.Continuous postoperative blood glucose monitoring and control by artificial pancreas in patients having pancreatic resection: A Prospective Randomized Clinical Trial. Arch Surg, 2009; 144(10):933–937.
36.
LeelarathnaL, EnglishSW, ThabitH, et al.Feasibility of fully automated closed-loop glucose control using continuous subcutaneous glucose measurements in critical illness: A Randomized Controlled Trial. Crit Care, 2013; 17(4):R159.
37.
OkabayashiT, ShimaY, SumiyoshiT, et al.Intensive versus intermediate glucose control in surgical intensive care unit patients. Diabetes Care, 2014; 37(6):1516–1524.
38.
OkabayashiT, HnazakiK, NishimoriI, et al.Continuous post-operative blood glucose monitoring and control using a closed-loop system in patients undergoing hepatic resection. Dig Dis Sci, 2008; 53(5):1405–1410.
39.
MitaN, KawahitoS, SogaT, et al.Strict blood glucose control by an artificial endocrine pancreas during hepatectomy may prevent postoperative acute kidney injury. J Artif Organs, 2017; 20(1):76–83.
40.
NamikawaT, MunekageM, KitagawaH, et al.Comparison between a novel and conventional artificial pancreas for perioperative glycemic control using a closed-loop system. J Artif Organs, 2017; 20(1):84–90.
41.
SoyamaA, KugiyamaT, HaraT, et al.Efficacy of an artificial pancreas device for achieving tight perioperative glycemic control in living donor liver transplantation. Artif Organs, 2019; 43(3):270–277.
42.
TamuraT, YatabeT, NamikawaT, et al.Glucose control using a closed-loop device decreases inflammation after cardiovascular surgery without increasing hypoglycemia risk. J Artif Organs, 2019; 22(2):154–159.
43.
UemuraH, SekiyaN, MitsunoM, et al.Usefulness of glycemic control using an artificial pancreas apparatus for cardiovascular surgery. ASAIO J, 2019; 65(5):503–508.
44.
AkaboriH, TaniM, KitamuraN, et al.Perioperative tight glycemic control using artificial pancreas decreases infectious complications via suppression of inflammatory cytokines in patients who underwent pancreaticoduodenectomy: A Prospective, Non-Randomized Clinical Trial. Am J Surg, 2020; 220(2):365–371.
45.
YoshimotoT, IkemotoT, MorineY, et al.Impact of using a perioperative artificial endocrine pancreas in pancreatic resection. Ann Gastroenterol Surg, 2020; 4(5):591–596.
46.
AizawaK, MuraokaA, KurumisawaS, et al.Artificial endocrine pancreas with a closed-loop system effectively suppresses the accelerated hyperglycemic status after reperfusion during aortic surgery. Gen Thorac Cardiovasc Surg, 2021; 69(1):14–18.
47.
ShinU, NaokoH, MichinoriT, et al.Utility of bedside artificial pancreas for postoperative glycemic control in cardiac surgery. J Artif Organs, 2021; 24(2):225–233.
48.
YatabeT, YamazakiR, KitagawaH, et al.The evaluation of the ability of closed-loop glycemic control device to maintain the blood glucose concentration in intensive care unit patients. Crit Care Med, 2011; 39(3):575–578.
49.
HanazakiK, KitagawaH, YatabeT, et al.Perioperative intensive insulin therapy using an artificial endocrine pancreas with closed-loop glycemic control system: The effects of no hypoglycemia. Am J Surg, 2014; 207(6):935–941.
50.
KitagawaH, YatabeT, NamikawaT, et al.Postoperative closed-loop glycemic control using an artificial pancreas in patients after esophagectomy. Anticancer Res, 2016; 36(8):4063–4067.
51.
HayashiH, TakamuraH, GabataR, et al.Induction of artificial pancreas in liver transplant recipients: Preliminary experience with an insightful message. Ann Transplant, 2017; 22:590–597.
52.
HayashiH, TajimaH, HanazakiK, et al.Safety of artificial pancreas in hepato-biliary-pancreatic surgery: A Prospective Study. Asian J Surg, 2020; 43(1):201–206.
53.
NewtonCA, SmileyD, BodeBW, et al.A comparison study of continuous insulin infusion protocols in the medical intensive care unit: Computer-guided vs. standard column-based algorithms. J Hosp Med, 2010; 5(8):432–437.
54.
DuboisJ, Van HerpeT, van HooijdonkRT, et al.Software-guided versus nurse-directed blood glucose control in critically ill patients: The LOGIC-2 multicenter randomized controlled clinical trial. Crit Care, 2017; 21(1):212.
55.
UllalJ, AloiJA, Reyes-UmpierrezD, et al.Comparison of computer-guided versus standard insulin infusion regimens in patients with diabetic ketoacidosis. J Diabetes Sci Technol, 2018; 12(1):39–46.
56.
HanazakiK, MaedaH, OkabayashiT. Tight perioperative glycemic control using an artificial endocrine pancreas. Surg Today, 2010; 40(1):1–7.
57.
HanazakiK, TaniokaN, MunekageM, et al.Closed-loop artificial endocrine pancreas from Japan. Artif Organs, 2021; 45(9):958–967.
58.
SheldenD, AteyaM, JensenA, et al.Improving hospital glucometrics, workflow, and outcomes with a computerized intravenous insulin dose calculator built into the electronic health record. J Diabetes Sci Technol, 2021; 15(2):271–278.
59.
MichaelAR, MarkR, ZoeD, et al.Smart agent system for insulin infusion protocol management: A simulation-based human factors evaluation study. BMJ Quality &Amp;Amp; Safety, 2021; 30(11):893.
60.
American Diabetes Association Professional Practice Committee. Management of diabetes in pregnancy: Standards of care in diabetes—2024. Diabetes Care, 2024; 47(Suppl 1):S282–S294.
61.
LimbachiaV, NunneyI, PageDJ, et al.The effect of different types of oral or intravenous corticosteroids on capillary blood glucose levels in hospitalized inpatients with and without diabetes. Clin Ther, 2024; 46(2):e59–e63.
62.
NguyenS, DavisGM, VasudevanMM. Clinical practice update: inpatient insulin pump and integrated insulin delivery systems. In: Diabetes Management in Hospitalized Patients: A Comprehensive Clinical Guide. (Schulman-RosenbaumRC., ed.) Springer International Publishing; Cham; 2023, pp. 95–116.
63.
Bionic Pancreas ResearchG, RussellSJ, BeckRW, et al.Multicenter, randomized trial of a bionic pancreas in type 1 diabetes. N Engl J Med, 2022; 387(13):1161–1172.
64.
ShalitR, MinskyN, Laron-HirshM, et al.Unannounced meal challenges using an advanced hybrid closed-loop system. Diabetes Technol Ther, 2023; 25(9):579–588.
65.
LaugesenC, RitschelT, RanjanAG, et al.Impact of missed and late meal boluses on glycemic outcomes in automated insulin delivery-treated children and adolescents with type 1 diabetes: A Two-Center, Population-Based Cohort Study. Diabetes Technol Ther, 2024.
66.
SvehlikovaE, AshcroftNL, GatschelhoferC, et al.Pharmacokinetics and pharmacodynamics of a novel U500 insulin aspart formulation: A randomized, double-blind, crossover study in people with type 1 diabetes. Diabetes Care, 2023; 46(4):757–764.
67.
HughesMS, DouvasJL, Layfield-BryanM, et al.Frequency and detection of insulin infusion site failure in the type 1 diabetes exchange online community. Diabetes Technol Ther, 2023; 25(6):426–430.
68.
NevesALD, MartinsLEG, GabbayMAL, et al.Insulin infusion sets associated with adverse events: Strategies for improved diabetes education. Front Med (Lausanne), 2023; 10:1275394.
69.
KalusA, ShinoharaMM, WangR, et al.Evaluation of insulin pump infusion sites in type 1 diabetes: The DERMIS Study. Diabetes Care, 2023; 46(9):1626–1632.
70.
Ariza-AndracaCR, Altamirano-BustamanteE, Frati-MunariAC, et al.Delayed insulin absorption due to subcutaneous edema. Arch Invest Med (Mex), 1991; 22(2):229–233.
71.
KastnerJR, EislerG, TorjmanMC, et al.In vivo study of the inflammatory tissue response surrounding a novel extended-wear kink-resistant insulin infusion set prototype compared with a commercial control over two weeks of wear time. J Diabetes Sci Technol, 2023; 17(6):1563–1572.
72.
BrazgR, GargSK, BhargavaA, et al.Evaluation of extended infusion set performance in adults with type 1 diabetes: Infusion set survival rate and glycemic outcomes from a Pivotal Trial. Diabetes Technol Ther, 2022; 24(8):535–543.
73.
HowsmonDP, BaysalN, BuckinghamBA, et al.Real-time detection of infusion site failures in a closed-loop artificial pancreas. J Diabetes Sci Technol, 2018; 12(3):599–607.
74.
BlancoLE, WilcoxJH, HughesMS, LalRA. Development of a real-time force-based algorithm for infusion failure detection. J Diabetes Sci Technol, 2024; 18(6):1313–1323.
75.
ButterfieldRD, SimsNM. Performance of a Continuous Subcutaneous Insulin Infusion (CSII) pump with acoustic volume and flow sensing in simulated HighConsequence situations. IEEE Open J Eng Med Biol, 2024; 5:593–599.
76.
JaromyM, MillerJD. Potential clinical applications for continuous ketone monitoring in the hospitalized patient with diabetes. Curr Diab Rep, 2022; 22(10):501–510.
SpanakisEK, CookCB, KulasaK, et al.A consensus statement for continuous glucose monitoring metrics for inpatient clinical trials. J Diabetes Sci Technol, 2023; 17(6):1527–1552.
79.
ZeladaH, Perez-GuzmanMC, ChernavvskyDR, GalindoRJ. Continuous glucose monitoring for inpatient diabetes management: An update on current evidence and practice. Endocr Connect, 2023; 12(10).
80.
DavisGM, SpanakisEK, MigdalAL, et al.Accuracy of Dexcom G6 continuous glucose monitoring in non–critically ill hospitalized patients with diabetes. Diabetes Care, 2021; 44(7):1641–1646.
81.
MillerEM. Using continuous glucose monitoring in clinical practice. Clin Diabetes, 2020; 38(5):429–438.
82.
Perez-GuzmanMC, DugganE, GibanicaS, et al.Continuous glucose monitoring in the operating room and cardiac intensive care unit. Diabetes Care, 2021; 44(3):e50–e52.
83.
MesserLH, BergetC, BeatsonC, et al.Preserving skin integrity with chronic device use in diabetes. Diabetes Technol Ther, 2018; 20(S2):S254–S264.
84.
MenshBD, WisniewskiNA, NeilBM, BurnettDR. Susceptibility of interstitial continuous glucose monitor performance to sleeping position. J Diabetes Sci Technol, 2013; 7(4):863–870.
85.
DavisGM, FauldsE, WalkerT, et al.Remote continuous glucose monitoring with a computerized insulin infusion protocol for critically ill patients in a COVID-19 medical ICU: Proof of concept. Diabetes Care, 2021; 44(4):1055–1058.
86.
Voglová HagerfB, ProtusM, NemetovaL, et al.Accuracy and feasibility of real-time continuous glucose monitoring in critically ill patients after abdominal surgery and solid organ transplantation. Diabetes Care, 2024; 47(6):956–963.
87.
TuliS, TuliS, WanderG, et al.Next generation technologies for smart healthcare: Challenges, vision, model, trends and future directions. Internet Technology Letters, 2020; 3(2):e145.
88.
GalindoRJ, AleppoG, KlonoffDC, et al.Implementation of continuous glucose monitoring in the hospital: Emergent considerations for remote glucose monitoring during the COVID-19 pandemic. J Diabetes Sci Technol, 2020; 14(4):822–832.
89.
Spierling BagsicSR, FortmannAL, BelascoR, et al.Real-time continuous glucose monitoring in the hospital: A real-world experience. J Diabetes Sci Technol, 2023; 17(3):656–666.
90.
MorrisZS, WoodingS, GrantJ. The answer is 17 years, what is the question: Understanding time lags in translational research. J R Soc Med, 2011; 104(12):510–520.
91.
ConsidineEG, SherrJL. Real-world evidence of automated insulin delivery system use. Diabetes Technol Ther, 2024; 26(S3):53–65.
92.
OECD. Length of hospital stay (indicator). OECD; 2024.
93.
NavatheAS, LiaoJM, WangE, et al.Association of patient outcomes with bundled payments among hospitalized patients attributed to accountable care organizations. JAMA Health Forum, 2021; 2(8):e212131.
94.
GluckmanTJ, SpinelliKJ, WangM, et al.Trends in diagnosis related groups for inpatient admissions and associated changes in payment from 2012 to 2016. JAMA Netw Open, 2020; 3(12):e2028470.
95.
HernandezJ, MachaczSF, RobinsonJC. US hospital payment adjustments for innovative technology lag behind those in Germany, France, and Japan. Health Aff (Millwood), 2015; 34(2):261–270.
96.
KhanSA, ZilbermintM. Centers for Medicare & Medicaid Services’ Hospital harm measures for severe hypoglycemia and hyperglycemia: Is your hospital ready? Diabetes Spectr, 2022; 35(4):391–397.
